دورية أكاديمية
أعرض في EDS

Survival, prognostic factors and rates of leukemic transformation in 381 untreated patients with MDS and del(5q): A multicenter study.

التفاصيل البيبلوغرافية
العنوان: Survival, prognostic factors and rates of leukemic transformation in 381 untreated patients with MDS and del(5q): A multicenter study.
المؤلفون: Germing, U1, Lauseker, M2, Hildebrandt, B3, Symeonidis, A4, Cermak, J5, Fenaux, P6, Kelaidi, C6, Pfeilstöcker, M7, Nösslinger, T7, Sekeres, M8, Maciejewski, J8, Haase, D9, Schanz, J9, Seymour, J10, Kenealy, M10, Weide, R11, Lübbert, M12, Platzbecker, U13, Valent, P14, Götze, K15
المصدر: Leukemia (08876924). Jun2012, Vol. 26 Issue 6, p1286-1292. 7p. 7 Charts, 5 Graphs.
مصطلحات موضوعية: *MYELODYSPLASTIC syndromes, *ACUTE myeloid leukemia, *PROGNOSIS, *DISEASE progression, *BLOOD transfusion
مستخلص: Myelodysplastic syndromes (MDS) with del(5q) are considered to have a benign course of the disease. In order to address the issue of the propensity of those patients to progress to acute myeloid leukemia (AML), data on 381 untreated patients with MDS and del(5q) characterized by low or intermediate I International Prognostic Scoring System (IPSS) risk score were collected from nine centers and registries. Median survival of the entire group was 74 months. Transfusion-dependent patients had a median survival of 44 months vs 97 months for transfusion-independent patients (P<0.0001). Transfusion need at diagnosis was the most important patient characteristic for survival. Of the 381 patients, 48 (12.6%) progressed to AML. The cumulative progression rate calculated using the Kaplan-Meier method was 4.9% at 2 years and 17.6% at 5 years. Factors associated with the risk of AML transformation were high-risk World Health Organization adapted Prognostic Scoring System (WPSS) score, marrow blast count >5% and red-cell transfusion dependency at diagnosis. In conclusion, patients with MDS and del(5q) are facing a considerable risk of AML transformation. More detailed cytogenetic and molecular studies may help to identify the patients at risk of progression. [ABSTRACT FROM AUTHOR]
قاعدة البيانات: Academic Search Index
ResultId 1
Header asx
Academic Search Index
76349193
1204
6
Academic Journal
academicJournal
1204.33728027344
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=asx&AN=76349193&custid=s6537998&authtype=sso
FullText Array ( [Availability] => 0 )
Array ( [0] => Array ( [Url] => https://resolver.ebscohost.com/openurl?custid=s6537998&groupid=main&authtype=ip,guest&sid=EBSCO:asx&genre=article&issn=08876924&ISBN=&volume=26&issue=6&date=20120601&spage=1286&pages=1286-1292&title=Leukemia (08876924)&atitle=Survival%2C%20prognostic%20factors%20and%20rates%20of%20leukemic%20transformation%20in%20381%20untreated%20patients%20with%20MDS%20and%20del%285q%29%3A%20A%20multicenter%20study.&id=DOI:10.1038/leu.2011.391 [Name] => Full Text Finder (s6537998api) [Category] => fullText [Text] => Full Text Finder [Icon] => https://imageserver.ebscohost.com/branding/images/FTF.gif [MouseOverText] => Full Text Finder ) )
Items Array ( [Name] => Title [Label] => Title [Group] => Ti [Data] => Survival, prognostic factors and rates of leukemic transformation in 381 untreated patients with MDS and del(5q): A multicenter study. )
Array ( [Name] => Author [Label] => Authors [Group] => Au [Data] => &lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Germing%2C+U%22&quot;&gt;Germing, U&lt;/searchLink&gt;&lt;relatesTo&gt;1&lt;/relatesTo&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Lauseker%2C+M%22&quot;&gt;Lauseker, M&lt;/searchLink&gt;&lt;relatesTo&gt;2&lt;/relatesTo&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Hildebrandt%2C+B%22&quot;&gt;Hildebrandt, B&lt;/searchLink&gt;&lt;relatesTo&gt;3&lt;/relatesTo&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Symeonidis%2C+A%22&quot;&gt;Symeonidis, A&lt;/searchLink&gt;&lt;relatesTo&gt;4&lt;/relatesTo&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Cermak%2C+J%22&quot;&gt;Cermak, J&lt;/searchLink&gt;&lt;relatesTo&gt;5&lt;/relatesTo&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Fenaux%2C+P%22&quot;&gt;Fenaux, P&lt;/searchLink&gt;&lt;relatesTo&gt;6&lt;/relatesTo&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Kelaidi%2C+C%22&quot;&gt;Kelaidi, C&lt;/searchLink&gt;&lt;relatesTo&gt;6&lt;/relatesTo&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Pfeilst&#246;cker%2C+M%22&quot;&gt;Pfeilst&#246;cker, M&lt;/searchLink&gt;&lt;relatesTo&gt;7&lt;/relatesTo&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22N&#246;sslinger%2C+T%22&quot;&gt;N&#246;sslinger, T&lt;/searchLink&gt;&lt;relatesTo&gt;7&lt;/relatesTo&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Sekeres%2C+M%22&quot;&gt;Sekeres, M&lt;/searchLink&gt;&lt;relatesTo&gt;8&lt;/relatesTo&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Maciejewski%2C+J%22&quot;&gt;Maciejewski, J&lt;/searchLink&gt;&lt;relatesTo&gt;8&lt;/relatesTo&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Haase%2C+D%22&quot;&gt;Haase, D&lt;/searchLink&gt;&lt;relatesTo&gt;9&lt;/relatesTo&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Schanz%2C+J%22&quot;&gt;Schanz, J&lt;/searchLink&gt;&lt;relatesTo&gt;9&lt;/relatesTo&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Seymour%2C+J%22&quot;&gt;Seymour, J&lt;/searchLink&gt;&lt;relatesTo&gt;10&lt;/relatesTo&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Kenealy%2C+M%22&quot;&gt;Kenealy, M&lt;/searchLink&gt;&lt;relatesTo&gt;10&lt;/relatesTo&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Weide%2C+R%22&quot;&gt;Weide, R&lt;/searchLink&gt;&lt;relatesTo&gt;11&lt;/relatesTo&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22L&#252;bbert%2C+M%22&quot;&gt;L&#252;bbert, M&lt;/searchLink&gt;&lt;relatesTo&gt;12&lt;/relatesTo&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Platzbecker%2C+U%22&quot;&gt;Platzbecker, U&lt;/searchLink&gt;&lt;relatesTo&gt;13&lt;/relatesTo&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Valent%2C+P%22&quot;&gt;Valent, P&lt;/searchLink&gt;&lt;relatesTo&gt;14&lt;/relatesTo&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22G&#246;tze%2C+K%22&quot;&gt;G&#246;tze, K&lt;/searchLink&gt;&lt;relatesTo&gt;15&lt;/relatesTo&gt; )
Array ( [Name] => TitleSource [Label] => Source [Group] => Src [Data] => &lt;searchLink fieldCode=&quot;JN&quot; term=&quot;%22Leukemia+%2808876924%29%22&quot;&gt;Leukemia (08876924)&lt;/searchLink&gt;. Jun2012, Vol. 26 Issue 6, p1286-1292. 7p. 7 Charts, 5 Graphs. )
Array ( [Name] => Subject [Label] => Subject Terms [Group] => Su [Data] => *&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22MYELODYSPLASTIC+syndromes%22&quot;&gt;MYELODYSPLASTIC syndromes&lt;/searchLink&gt;&lt;br /&gt;*&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22ACUTE+myeloid+leukemia%22&quot;&gt;ACUTE myeloid leukemia&lt;/searchLink&gt;&lt;br /&gt;*&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22PROGNOSIS%22&quot;&gt;PROGNOSIS&lt;/searchLink&gt;&lt;br /&gt;*&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22DISEASE+progression%22&quot;&gt;DISEASE progression&lt;/searchLink&gt;&lt;br /&gt;*&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22BLOOD+transfusion%22&quot;&gt;BLOOD transfusion&lt;/searchLink&gt; )
Array ( [Name] => Abstract [Label] => Abstract [Group] => Ab [Data] => Myelodysplastic syndromes (MDS) with del(5q) are considered to have a benign course of the disease. In order to address the issue of the propensity of those patients to progress to acute myeloid leukemia (AML), data on 381 untreated patients with MDS and del(5q) characterized by low or intermediate I International Prognostic Scoring System (IPSS) risk score were collected from nine centers and registries. Median survival of the entire group was 74 months. Transfusion-dependent patients had a median survival of 44 months vs 97 months for transfusion-independent patients (P&lt;0.0001). Transfusion need at diagnosis was the most important patient characteristic for survival. Of the 381 patients, 48 (12.6%) progressed to AML. The cumulative progression rate calculated using the Kaplan-Meier method was 4.9% at 2 years and 17.6% at 5 years. Factors associated with the risk of AML transformation were high-risk World Health Organization adapted Prognostic Scoring System (WPSS) score, marrow blast count &gt;5% and red-cell transfusion dependency at diagnosis. In conclusion, patients with MDS and del(5q) are facing a considerable risk of AML transformation. More detailed cytogenetic and molecular studies may help to identify the patients at risk of progression. [ABSTRACT FROM AUTHOR] )
RecordInfo Array ( [BibEntity] => Array ( [Identifiers] => Array ( [0] => Array ( [Type] => doi [Value] => 10.1038/leu.2011.391 ) ) [Languages] => Array ( [0] => Array ( [Code] => eng [Text] => English ) ) [PhysicalDescription] => Array ( [Pagination] => Array ( [PageCount] => 7 [StartPage] => 1286 ) ) [Subjects] => Array ( [0] => Array ( [SubjectFull] => MYELODYSPLASTIC syndromes [Type] => general ) [1] => Array ( [SubjectFull] => ACUTE myeloid leukemia [Type] => general ) [2] => Array ( [SubjectFull] => PROGNOSIS [Type] => general ) [3] => Array ( [SubjectFull] => DISEASE progression [Type] => general ) [4] => Array ( [SubjectFull] => BLOOD transfusion [Type] => general ) ) [Titles] => Array ( [0] => Array ( [TitleFull] => Survival, prognostic factors and rates of leukemic transformation in 381 untreated patients with MDS and del(5q): A multicenter study. [Type] => main ) ) ) [BibRelationships] => Array ( [HasContributorRelationships] => Array ( [0] => Array ( [PersonEntity] => Array ( [Name] => Array ( [NameFull] => Germing, U ) ) ) [1] => Array ( [PersonEntity] => Array ( [Name] => Array ( [NameFull] => Lauseker, M ) ) ) [2] => Array ( [PersonEntity] => Array ( [Name] => Array ( [NameFull] => Hildebrandt, B ) ) ) [3] => Array ( [PersonEntity] => Array ( [Name] => Array ( [NameFull] => Symeonidis, A ) ) ) [4] => Array ( [PersonEntity] => Array ( [Name] => Array ( [NameFull] => Cermak, J ) ) ) [5] => Array ( [PersonEntity] => Array ( [Name] => Array ( [NameFull] => Fenaux, P ) ) ) [6] => Array ( [PersonEntity] => Array ( [Name] => Array ( [NameFull] => Kelaidi, C ) ) ) [7] => Array ( [PersonEntity] => Array ( [Name] => Array ( [NameFull] => Pfeilstöcker, M ) ) ) [8] => Array ( [PersonEntity] => Array ( [Name] => Array ( [NameFull] => Nösslinger, T ) ) ) [9] => Array ( [PersonEntity] => Array ( [Name] => Array ( [NameFull] => Sekeres, M ) ) ) [10] => Array ( [PersonEntity] => Array ( [Name] => Array ( [NameFull] => Maciejewski, J ) ) ) [11] => Array ( [PersonEntity] => Array ( [Name] => Array ( [NameFull] => Haase, D ) ) ) [12] => Array ( [PersonEntity] => Array ( [Name] => Array ( [NameFull] => Schanz, J ) ) ) [13] => Array ( [PersonEntity] => Array ( [Name] => Array ( [NameFull] => Seymour, J ) ) ) [14] => Array ( [PersonEntity] => Array ( [Name] => Array ( [NameFull] => Kenealy, M ) ) ) [15] => Array ( [PersonEntity] => Array ( [Name] => Array ( [NameFull] => Weide, R ) ) ) [16] => Array ( [PersonEntity] => Array ( [Name] => Array ( [NameFull] => Lübbert, M ) ) ) [17] => Array ( [PersonEntity] => Array ( [Name] => Array ( [NameFull] => Platzbecker, U ) ) ) [18] => Array ( [PersonEntity] => Array ( [Name] => Array ( [NameFull] => Valent, P ) ) ) [19] => Array ( [PersonEntity] => Array ( [Name] => Array ( [NameFull] => Götze, K ) ) ) ) [IsPartOfRelationships] => Array ( [0] => Array ( [BibEntity] => Array ( [Dates] => Array ( [0] => Array ( [D] => 01 [M] => 06 [Text] => Jun2012 [Type] => published [Y] => 2012 ) ) [Identifiers] => Array ( [0] => Array ( [Type] => issn-print [Value] => 08876924 ) ) [Numbering] => Array ( [0] => Array ( [Type] => volume [Value] => 26 ) [1] => Array ( [Type] => issue [Value] => 6 ) ) [Titles] => Array ( [0] => Array ( [TitleFull] => Leukemia (08876924) [Type] => main ) ) ) ) ) ) )
IllustrationInfo